What was the market valuation of the GCC herpes zoster market in 2024?

The market valuation was $10.5 Million in 2024. Read More

What is the projected market valuation for the GCC herpes zoster market by 2035?

The projected valuation for 2035 is $19.96 Million. Read More

What is the expected CAGR for the GCC herpes zoster market during the forecast period 2025 - 2035?

The expected CAGR is 6.01% during the forecast period 2025 - 2035. Read More

Which companies are the key players in the GCC herpes zoster market?

Key players include GSK, Merck & Co, Pfizer, Sanofi, AstraZeneca, Bristol-Myers Squibb, Novartis, AbbVie, and Teva Pharmaceutical Industries. Read More

What are the main segments of the GCC herpes zoster market?

The main segments include Diagnosis, Treatment and Prevention, Route of Administration, and End User. Read More

What was the valuation for antiviral medications in the Treatment and Prevention segment in 2024?

The valuation for antiviral medications was $2.1 Million in 2024. Read More

What is the projected valuation for oral administration in the Route of Administration segment by 2035?

The projected valuation for oral administration is $5.92 Million by 2035. Read More

How much is expected to be spent on laboratory testing in the Diagnosis segment by 2035?

The expected spending on laboratory testing is $4.0 Million by 2035. Read More

What is the projected valuation for hospitals and clinics in the End User segment by 2035?

The projected valuation for hospitals and clinics is $5.95 Million by 2035. Read More

What is the expected growth trend for the GCC herpes zoster market?

The market appears to be on a growth trend, with a projected CAGR of 6.01% from 2025 - 2035. Read More

GCC Herpes Zoster Market

GCC Herpes Zoster Market Research Report By Diagnosis (Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing, Others), By Treatment and Prevention (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines, Others), By Route of Administration (Oral, Topical, Others) and By End User (Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings, Others) -Forecast to 2035

Forecast Period

2025 - 2035

CAGR

6.01%

2024 Market Size

$ 10.5 Million

2035 Market Size

$ 19.96 Million

Healthcare ● Updated April 2026 Report ID: MRFR/HC/51975-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Diagnosis (USD Million)
  1. 4.1.1 Laboratory Testing
  2. 4.1.2 Immunofluorescent Microscopy
  3. 4.1.3 Real-Time Polymerase Chain Reaction (PCR)
  4. 4.1.4 Serological Testing
  5. 4.1.5 Others
2. 4.2 Industrial Automation & Equipment, BY Treatment and Prevention (USD Million)
  1. 4.2.1 Antiviral Medications
  2. 4.2.2 Narcotic Medications
  3. 4.2.3 Anti-Inflammatory Medications
  4. 4.2.4 Antihistamines
  5. 4.2.5 Anticonvulsants
  6. 4.2.6 Capsaicin
  7. 4.2.7 Numbing Creams, Gels, or Patches
  8. 4.2.8 Vaccines
  9. 4.2.9 Others
3. 4.3 Industrial Automation & Equipment, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Topical
  3. 4.3.3 Others
4. 4.4 Industrial Automation & Equipment, BY End User (USD Million)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Diagnostic Centers
  3. 4.4.3 Research & Academic Institutes
  4. 4.4.4 Home Care Settings
  5. 4.4.5 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GSK (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 GCC MARKET ANALYSIS BY TREATMENT AND PREVENTION
4. 6.4 GCC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 GCC MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT AND PREVENTION, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT AND PREVENTION, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT AND PREVENTION, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Herpes Zoster Market Segmentation

GCC Herpes Zoster Market By Diagnosis (USD Million, 2025-2035)

Laboratory Testing
Immunofluorescent Microscopy
Real-Time Polymerase Chain Reaction (PCR)
Serological Testing
Others

GCC Herpes Zoster Market By Treatment and Prevention (USD Million, 2025-2035)

Antiviral Medications
Narcotic Medications
Anti-Inflammatory Medications
Antihistamines
Anticonvulsants
Capsaicin
Numbing Creams, Gels, or Patches
Vaccines
Others

GCC Herpes Zoster Market By Route of Administration (USD Million, 2025-2035)

Oral
Topical
Others

GCC Herpes Zoster Market By End User (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Research & Academic Institutes
Home Care Settings
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”